Publications by authors named "Christiana Mo"
Article Synopsis
- Claudins are important proteins that maintain the structure of tight junctions in cells, impacting crucial processes like development and cell death, with abnormal levels linked to various cancers, especially in tissues.
- The review discusses the diverse roles of claudins in cancer, particularly focusing on hepato-pancreato-biliary cancers, and suggests they could be key targets for new therapies.
- Current treatments targeting claudins, including different types of immunotherapies, show promise in early studies, but researchers face challenges due to the similarities between claudin proteins and their overlapping roles in the body.
An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer.
Clin Colorectal Cancer
December 2024
Substantial progress is being made in the development of novel therapies directed against colorectal cancer. The discovery of various molecular markers and advances in tumor profiling have facilitated the development of new targeted agents and immunotherapy. Not only have these drugs improved progression-free survival and even overall survival in some cases, but their related outcomes have also raised questions as to how to best combine or sequence therapies for even greater efficacy.
View Article and Find Full Text PDFHuman epidermal growth factor 2 (HER2) is a tyrosine kinase receptor that interacts with multiple signaling pathways related to cellular growth and proliferation. Overexpression or amplification of HER2 is linked to various malignancies, and there have been decades of research dedicated to targeting HER2. Despite the landmark ToGA trial, progress in HER2-positive gastrointestinal malignancies has been hampered by drug resistance.
View Article and Find Full Text PDFArticle Synopsis
- CDK9 is a key regulator of mRNA transcription and is increasingly recognized as a target for cancer therapy due to its role in promoting cancer cell growth and poor patient outcomes.
- Recent research is expanding the focus on CDK9's implications not just in blood cancers, but also in solid tumors, where it is often overexpressed and drives oncogenic processes.
- This review highlights recent findings about CDK9 in solid tumors, evaluates small molecule inhibitors targeting CDK9, and discusses the latest clinical trial results while addressing considerations for enhancing the effectiveness of these therapies.
Pancreatic neuroendocrine tumors (PanNETs) are rare neoplasms that arise in the neuroendocrine cells of the pancreas. Although their clinical presentations differ depending on cell type, most are indolent, whereas others cause noteworthy hormone-related symptoms. The increasing incidence of PanNETs, attributed to improved diagnostic modalities, demonstrates advances in current standard of care.
View Article and Find Full Text PDF